Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance

Cellular Oncology

Volumn 34, Issue 1, 2011, Pages 33-44

  Xiang, Qing Feng ^a   Wang, Fang ^b   Su, Xiao Dong ^b   Liang, Yong Ju ^b   Zheng, Li Sheng ^b   Mi, Yan Jun ^b   Chen, Wei Qiang ^a   Fu, Li Wu ^b  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

ABCB1 P glycoprotein; ATP binding cassette transporters; BIBF 1120; Multidrug resistance

Indexed keywords

CISPLATIN; DOXORUBICIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; NINTEDANIB; PACLITAXEL; PROTEIN KINASE B; RHODAMINE 123; GLYCOPROTEIN P; INDOLE DERIVATIVE; INTEDANIB; MITOGEN ACTIVATED PROTEIN KINASE; VERAPAMIL;

ARTICLE; CELL ASSAY; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL DEATH; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

CELL DEATH; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG SCREENING ASSAYS, ANTITUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; P-GLYCOPROTEIN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RHODAMINE 123; VERAPAMIL;

EID: 80052546409     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-010-0003-7     Document Type: Article

References (52)

1. M.M. Gottesman, T. Fojo, S.E. Bates, Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58 (2002) (Pubitemid 37328807)
2. R. Perez-Tomas, Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem. 13, 1859-1876 (2006)
3. M. Dean, A. Rzhetsky, R. Allikmets, The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11, 1156-1166 (2001) (Pubitemid 32677289)
4. C.H. Choi, ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 5, 30 (2005)
5. U.A. Germann, P-glycoprotein-a mediator of multidrug resistance in tumour cells. Eur. J. Cancer 32A, 927-944 (1996)
6. G.D. Leonard, T. Fojo, S.E. Bates, The role of ABC transporters in clinical practice. Oncologist 8, 411-424 (2003) (Pubitemid 37238869)
7. D.R. Hipfner, R.G. Deeley, S.P. Cole, Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta 1461, 359-376 (1999)
8. G. Szakacs, J.P. Annereau, S. Lababidi, U. Shankavaram, A. Arciello, K.J. Bussey, W. Reinhold, Y. Guo, G.D. Kruh, M. Reimers, J.N. Weinstein, M.M. Gottesman, Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6, 129-137 (2004) (Pubitemid 39485685)
9. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, M.M. Gottesman, Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219-234 (2006) (Pubitemid 43336035)
10. L.A. Doyle, D.D. Ross, Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22, 7340-7358 (2003) (Pubitemid 37487163)
11. L.A. Doyle, W. Yang, L.V. Abruzzo, T. Krogmann, Y. Gao, A.K. Rishi, D.D. Ross, A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl Acad. Sci. USA 95, 15665-15670 (1998) (Pubitemid 29018757)
12. N. Haraguchi, T. Utsunomiya, H. Inoue, F. Tanaka, K. Mimori, G. F. Barnard, M. Mori, Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24, 506-513 (2006) (Pubitemid 44464754)
13. H.M. Coley, Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Meth. Mol. Biol. 596, 341-358 (2010)
14. M. Dean, T. Fojo, S. Bates, Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284 (2005) (Pubitemid 40488633)
15. F. Hilberg, G.J. Roth,M. Krssak, S. Kautschitsch,W. Sommergruber, U. Tontsch-Grunt, P. Garin-Chesa, G. Bader, A. Zoephel, J. Quant, A. Heckel, W.J. Rettig, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68, 4774-4782 (2008)
16. M. Reck, BIBF 1120 for the treatment of non-small cell lung cancer. Expert Opin. Investig. Drugs 19, 789-794 (2010)
17. C.L. Dai, A.K. Tiwari, C.P. Wu, X.D. Su, S.R. Wang, D.G. Liu, C.R. Ashby Jr., Y. Huang, R.W. Robey, Y.J. Liang, L.M. Chen, C. J. Shi, S.V. Ambudkar, Z.S. Chen, L.W. Fu, Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 68, 7905-7914 (2008)
18. T. Kitazaki, M. Oka, Y. Nakamura, J. Tsurutani, S. Doi, M. Yasunaga, M. Takemura, H. Yabuuchi, H. Soda, S. Kohno, Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49, 337-343 (2005) (Pubitemid 41139146)
19. Z. Shi, X.X. Peng, I.W. Kim, S. Shukla, Q.S. Si, R.W. Robey, S.E. Bates, T. Shen, C.R. Ashby Jr., L.W. Fu, S.V. Ambudkar, Z.S. Chen, Erlotinib (Tarceva, OSI-774) antagonizes ATP-bindingcassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 67, 11012-11020 (2007) (Pubitemid 350145931)
20. L.Y. Tao, Y.J. Liang, F. Wang, L.M. Chen, Y.Y. Yan, C.L. Dai, L. W. Fu, Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother. Pharmacol. 64, 961-969 (2009)
21. L.S. Zheng, F. Wang, Y.H. Li, X. Zhang, L.M. Chen, Y.J. Liang, C.L. Dai, Y.Y. Yan, L.Y. Tao, Y.J. Mi, A.K. Yang, K.K. To, L.W. Fu, Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS ONE 4, e5172 (2009)
22. C.L. Dai, Y.J. Liang, Y.S. Wang, A.K. Tiwari, Y.Y. Yan, F. Wang, Z.S. Chen, X.Z. Tong, L.W. Fu, Sensitization of ABCG2- overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 279, 74-83 (2009)
23. F. Hilberg, I. Brandstetter, Efficacy of BIBF 1120, a potent triple angiokinase inhibitor, in models of human non-small cell lung cancer is augmented by chemotherapy: C7-03, Journal of Thoracic Oncology 2 (2007) S380 310.1097/1001. JTO.0000283231.0000276336.0000283201
24. A. du Bois, J. Huober, P. Stopfer, J. Pfisterer, P. Wimberger, S. Loibl, V.L. Reichardt, P. Harter, A phase I open-label doseescalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann. Oncol. 21, 370-375 (2010)
25. M. Reck, R. Kaiser, C. Eschbach, M. Stefanic, J. Love, U. Gatzemeier, J. von Pawel, Phase II double blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC): B1-03, Journal of Thoracic Oncology 2 (2007) S333-S334 310.1097/1001. JTO.0000283141.0000268423.c0000283145.
26. L. Fu, Y. Liang, L. Deng, Y. Ding, L. Chen, Y. Ye, X. Yang, Q. Pan, Characterization of tetrandrine, a potent inhibitor of Pglycoprotein- mediated multidrug resistance. Cancer Chemother. Pharmacol. 53, 349-356 (2004) (Pubitemid 38392360)
27. R.W. Robey, Y. Honjo, K. Morisaki, T.A. Nadjem, S. Runge, M. Risbood, M.S. Poruchynsky, S.E. Bates, Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br. J. Cancer 89, 1971-1978 (2003) (Pubitemid 37533279)
28. P.M. Tang, D.M. Zhang, N.H. Xuan, S.K. Tsui, M.M. Waye, S.K. Kong, W.P. Fong, K.P. Fung, Photodynamic therapy inhibits Pglycoprotein mediated multidrug resistance via JNK activation in human hepatocellular carcinoma using the photosensitizer pheophorbide a. Mol. Cancer 8, 56 (2009)
29. R. Tang, A.M. Faussat, P. Majdak, J.Y. Perrot, D. Chaoui, O. Legrand, J.P. Marie, Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing Pgp and MRP1. Leukemia 18, 1246-1251 (2004) (Pubitemid 39023135)
30. L.M. Chen, X.P. Wu, J.W. Ruan, Y.J. Liang, Y. Ding, Z. Shi, X.W. Wang, L.Q. Gu, L.W. Fu, Screening novel, potent multidrugresistant modulators from imidazole derivatives. Oncol. Res. 14, 355-362 (2004) (Pubitemid 39070676)
31. Z. Shi, Y.J. Liang, Z.S. Chen, X.W. Wang, X.H. Wang, Y. Ding, L.M. Chen, X.P. Yang, L.W. Fu, Reversal of MDR1/P-glycoprotein- mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol. Ther. 5, 39-47 (2006) (Pubitemid 43234976)
32. J.M. Ford, W.N. Hait, Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42, 155-199 (1990) (Pubitemid 20291782)
33. L.M. Chen, Y.J. Liang, J.W. Ruan, Y. Ding, X.W. Wang, Z. Shi, L. Q. Gu, X.P. Yang, L.W. Fu, Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. J. Pharm. Pharmacol. 56, 1061-1066 (2004) (Pubitemid 39140063)
34. H. Minderman, K.L. O'Loughlin, L. Pendyala, M.R. Baer, VX- 710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin. Cancer Res. 10, 1826-1834 (2004) (Pubitemid 38435574)
35. P. Limtrakul, O. Khantamat, K. Pintha, Inhibition of Pglycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract. Cancer Chemother. Pharmacol. 54, 525-530 (2004) (Pubitemid 40022248)
36. V. Gagnon, C. Van Themsche, S. Turner, V. Leblanc, E. Asselin, Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis 13, 259-271 (2008)
37. S.Y. Oh, J.H. Song, J.E. Gil, J.H. Kim, Y.I. Yeom, E.Y. Moon, ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel- resistance. Exp. Cell Res. 312, 1651-1657 (2006)
38. R.S. Herbst, Therapeutic options to target angiogenesis in human malignancies. Expert Opin. Emerg. Drugs 11, 635-650 (2006) (Pubitemid 44735590)
39. A. Morabito, E. De Maio, M. Di Maio, N. Normanno, F. Perrone, Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11, 753-764 (2006) (Pubitemid 44157563)
40. L. Zahiragic, C. Schliemann, R. Bieker, N.H. Thoennissen, K. Burow, C. Kramer, M. Zuhlsdorf, W.E. Berdel, R.M. Mesters, Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 21, 1310-1312 (2007) (Pubitemid 46831824)
41. F.J. Giles, W.T. Bellamy, Z. Estrov, S.M. O'Brien, S. Verstovsek, F. Ravandi, M. Beran, P. Bycott, Y. Pithavala, H. Steinfeldt, S.D. Reich, A.F. List, K.W. Yee, The anti-angiogenesis agent, AG- 013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk. Res. 30, 801-811 (2006) (Pubitemid 43816694)
42. O. Casanovas, D.J. Hicklin, G. Bergers, D. Hanahan, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309 (2005) (Pubitemid 41443415)
43. S.A. Antoniu, M.R. Kolb, Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. IDrugs 13, 332-345 (2010)
44. P.M. Ellis, R. Kaiser, Y. Zhao, P. Stopfer, S. Gyorffy, N. Hanna, Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated nonsmall cell lung cancer patients. Clin. Cancer Res. 16, 2881-2889 (2010)
45. J. Von Pawel, R. Kaiser, C. Eschbach, M. Stefanic, J. Love, U. Gatzemeier, M. Reck, A double blind phase II study of BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC), J Clin Oncol (Meeting Abstracts) 25, 7635 (2007)
46. G.A. Fisher, B.L. Lum, J. Hausdorff, B.I. Sikic, Pharmacological considerations in the modulation of multidrug resistance. Eur. J. Cancer 32A, 1082-1088 (1996)
47. Y.P. Hu, P. Pourquier, F. Doignon, M. Crouzet, J. Robert, Effects of modulators of multidrug resistance on the expression of the MDR1 gene on human KB cells in culture. Anticancer Drugs 7, 738-744 (1996) (Pubitemid 26388763)
48. K.A. West, S.S. Castillo, P.A. Dennis, Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat. 5, 234-248 (2002) (Pubitemid 36132805)
49. J.A. McCubrey, L.S. Steelman, W.H. Chappell, S.L. Abrams, E. W. Wong, F. Chang, B. Lehmann, D.M. Terrian, M. Milella, A. Tafuri, F. Stivala, M. Libra, J. Basecke, C. Evangelisti, A.M. Martelli, R.A. Franklin, Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 1773, 1263-1284 (2007) (Pubitemid 47125967)
50. C. Knuefermann, Y. Lu, B. Liu, W. Jin, K. Liang, L. Wu, M. Schmidt, G.B. Mills, J. Mendelsohn, Z. Fan, HER2/PI-3 K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22, 3205-3212 (2003) (Pubitemid 36712932)
51. R. Krishna, L.D. Mayer, Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11, 265-283 (2000)
52. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, M.M. Gottesman, Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39, 361-398 (1999) (Pubitemid 29222564)